Literature DB >> 15292464

Monitoring the progress of BK virus associated nephropathy in renal transplant recipients.

C Y William Tong1, Rachel Hilton, Eithne M E MacMahon, Lisa Brown, Panagiotis Pantelidis, Ian L Chrystie, I Michael Kidd, M Fahim Tungekar, James M Pattison.   

Abstract

BACKGROUND: Nephropathy associated with BK virus (BKVAN) has recently emerged as an important cause of allograft failure following renal transplantation. The aim of this study was to evaluate the effectiveness of laboratory markers in the follow-up of patients with BKVAN.
METHODS: Serial samples from seven renal transplant recipients with biopsy proven BKVAN were studied. The median follow-up time from diagnosis was 76 weeks. Intervention after the diagnosis of BKVAN included immunosuppression dose reduction, alternative immunosuppressive agents and/or antiviral therapy with cidofovir. Serial urine samples (n = 127) were collected for electron microscopy (EM), decoy cell detection and quantitative urine BK viral load using real-time polymerase chain reaction. Serum BK viral load was also measured serially (n = 72).
RESULTS: All patients showed a reduction in serum and urine viral load during the period of follow-up co-incident with the loss of decoy cells and negative urine EM. Urine samples that were negative for decoy cells or polyomavirus by EM had a urine viral load <10(6) copies/ml and a corresponding serum viral load <10(3) copies/ml. In paired serum/urine samples, there was a proportional relationship between serum and urine viral load with each urine viral load approximately 1000-fold higher than the corresponding serum level. Serum and urine viral loads that decreased to <200 and < 10(6) copies/ml, respectively, correlated with histological improvement.
CONCLUSION: Negative EM and absence of decoy cells could be used as broad indicators of a response to intervention. However, measurement of BK virus DNA level provided a wider dynamic range and could be a better choice for determining the extent of viral control.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292464     DOI: 10.1093/ndt/gfh391

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  Urine cytology screening for polyoma virus infection following renal transplantation: the Oxford experience.

Authors:  Thomas P Thamboo; Katie J M Jeffery; Peter J Friend; Gareth D H Turner; Ian S D Roberts
Journal:  J Clin Pathol       Date:  2006-12-08       Impact factor: 3.411

Review 2.  Modern uses of electron microscopy for detection of viruses.

Authors:  Cynthia S Goldsmith; Sara E Miller
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 3.  Polyomavirus-associated nephropathy.

Authors:  Cristina Costa; Rossana Cavallo
Journal:  World J Transplant       Date:  2012-12-24

Review 4.  Management of polyomavirus-associated nephropathy in renal transplant recipients.

Authors:  Dirk R J Kuypers
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

5.  The therapeutic effect of switching from tacrolimus to low-dose cyclosporine A in renal transplant recipients with BK virus nephropathy.

Authors:  Xu-Tao Chen; Jun Li; Rong-Hai Deng; Shi-Cong Yang; Yan-Yang Chen; Pei-Song Chen; Ze-Yuan Wang; Yang Huang; Chang-Xi Wang; Gang Huang
Journal:  Biosci Rep       Date:  2019-02-22       Impact factor: 3.840

Review 6.  Advances in BK Virus Complications in Organ Transplantation and Beyond.

Authors:  Abraham Cohen-Bucay; Silvia E Ramirez-Andrade; Craig E Gordon; Jean M Francis; Vipul C Chitalia
Journal:  Kidney Med       Date:  2020-10-11

Review 7.  Complications post renal transplantation: literature focus on BK virus nephropathy and diagnostic tools actually available.

Authors:  Monica Mischitelli; Anna Bellizzi; Elena Anzivino; Daniela Fioriti; Renzo Boldorini; Umberto Miglio; Fernanda Chiarini; Franco Di Monaco; Valeria Pietropaolo
Journal:  Virol J       Date:  2008-03-03       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.